Cyxone has received approval for cyclotide technology patent in the US

The US Patent Office has announced its approval of Cyxone's patent on the cyclotide technology.

Approval of Cyxone's patent application for cyclotide technology by the US Patent Office, was published on 27 September 2016, number 9,453,052.

In 2015 Cyxone acquired all rights to the cyclotide technology that was developed at the Medical University of Vienna and the University Clinic in Freiburg.

Cyxone's CEO Kjell Stenberg remarks:
"Approval of this US patent application has strengthened Cyxone's prospects prior to the commercial use of cyclotide drugs in the United States."

Contact
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: 070-716 80 09
E-mail: kjell.g.stenberg@cyxone.com
Adelgatan 21
221 22 Malmö
www.cyxone.com

This is information which Cyxone AB is required to publish under the EU Market Abuse Regulation. The information was provided by the auspices of the above contact person for publication on September 19, 2016 at. 14:45 CET.

About Cyxone
Cyxone AB (publ) is a biopharmaceutical company developing drugs based on cyclotides, a class of natural plant proteins. Cyclotide technology has the potential to provide new drugs offering beneficial pharmacological effects for diseases that currently lack effective and safe treatments. The company is focusing on the development of T20K, a substance which inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxones Certified Adviser on Nasdaq First North is Consensus Asset Management AB.